Primary Prevention of Cardiovascular Disease with Statins in Adults with HIV

A new guideline calls for broader use of statins in this population.

Sponsoring Organizations: U.S. Department of Health and Human Services Panel for the Use of Antiretroviral Agents in Adults and Adolescents with HIV; in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), and HIV Medicine Association

Background

The 2019 ACC/AHA guideline on primary prevention of cardiovascular disease listed HIV as a “risk-enhancing factor” that might influence a decision to initiate statins. In 2023, the REPRIEVE trial demonstrated that statins could lower the incidence of adverse cardiovascular events significantly in people with HIV, even if they otherwise were at low risk for cardiovascular disease (CVD; NEJM JW Gen Med Sep 1 2023 and N Engl J Med 2023; 389:687). Those compelling…

Reviewing Author

Christopher W. Goodman, MD

Disclosures

Nothing to disclose

Christopher W. Goodman, MD

Disclosures

Nothing to disclose

Primary Prevention of Cardiovascular Disease with Statins in Adults with HIV

Topics

Background

Reviewing Author